ICT-21

N/A

Report date: 2025/03/19 11:14:17

Base Information

Drug NameICT-21
Drug Alias NameICT-21
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAnti-Butyrophilin subfamily 3 member A1
TargetsButyrophilin subfamily 3 member A1
Therapy Area/IndicationsAutoimmune Diseases of the Nervous System
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesImCheck Therapeutics SAS
China Registration ClassN/A

Develop Information

Active CompaniesImCheck Therapeutics SAS
Inactive CompaniesN/A
Active IndicationsAutoimmune Diseases of the Nervous System
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A